Applicant, as named in the Orange Book

Janssen Prods

Johnson & Johnson · NYSE: JNJ

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Prezista on 26 Jun 2027. 7 products with live protection, 1 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Prezista NDA 021976 · 4 strengths darunavir	darunavir	26 Jun 2027 patent	patent
Prezista NDA 202895 darunavir	darunavir	26 Jun 2027 patent	patent
Edurant NDA 202022 rilpivirine hydrochloride	rilpivirine hydrochloride	15 Sep 2027 exclusivity	exclusivity
Yondelis NDA 207953 trabectedin	trabectedin	7 Jul 2028 patent	patent
Prezcobix NDA 205395 · 2 strengths cobicistat; darunavir ethanolate	cobicistat; darunavir ethanolate	6 Oct 2032 patent	patent
Edurant Ped NDA 219016 rilpivirine hydrochloride	rilpivirine hydrochloride	23 Oct 2037 patent	patent
Symtuza NDA 210455 cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	19 Jul 2038 patent, carve-out possible	patent, carve-out possible

Edurant · First generic approved · ANDA 218798, Somerset Theraps LlcApproved 29 Jan 2026Detected 25 Oct 2026
Edurant · Generic approved · ANDA 218798, Somerset Theraps LlcApproved 29 Jan 2026Detected 25 Oct 2026
Edurant · Generic approved · ANDA 219788, LaurusApproved 10 Jul 2026Detected 25 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026
Edurant · Enters 12-month window basis: exclusivityListed date 15 Sep 2027Detected 24 Oct 2026
Prezista · Enters 12-month window basis: patentListed date 26 Jun 2027Detected 24 Oct 2026

Products without listed protection (1)

Drug	Ingredient	Earliest generic entry	Basis
Prezcobix Ped NDA 220092 cobicistat; darunavir ethanolate	cobicistat; darunavir ethanolate	open now no listed protection	no listed protection